Core Viewpoint - QOL Medical is set to acquire Evoke Pharma for $11.00 per share in cash, representing a 139.7% premium over Evoke's recent Nasdaq closing price, with the transaction expected to close by the end of 2025 [1][2][5] Company Overview - Evoke Pharma focuses on developing treatments for gastrointestinal diseases, particularly its FDA-approved GIMOTI nasal spray for diabetic gastroparesis [9][10] - QOL Medical specializes in biopharmaceutical solutions for rare diseases and gastrointestinal conditions, aiming to enhance clinical outcomes and quality of life for patients [7][8] Transaction Details - The acquisition will be executed through a tender offer, with QOL Medical's subsidiary initiating the process to acquire all outstanding shares of Evoke at the specified cash price [4] - The transaction is not contingent on financing, as QOL Medical plans to use cash on hand for the acquisition [5] Strategic Rationale - The acquisition is seen as a strategic move to enhance QOL Medical's gastrointestinal portfolio, leveraging Evoke's innovative therapy that addresses significant unmet needs in the market [3][4] - Both companies' leadership expressed confidence in the alignment of their missions and the potential for growth in the gastrointestinal care sector [3]